Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 13Gastrointestinal 7Breast 3Thoracic 2Sarcoma 1Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Multiple Myeloma 10Neoplasms, Plasma Cell 4Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Leukemia 3Breast Neoplasms 3Ovarian Neoplasms 2Myeloproliferative Disorders 2Lymphoma 2Glioblastoma 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Plasma Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Trastuzumab 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1selinexor 1sapanisertib 1relatlimab 1pertuzumab 1pemigatinib 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Gemcitabine × Plasma cell × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡